Literature DB >> 31102730

Intravitreal nanoparticles for retinal delivery.

Xiaonan Huang1, Ying Chau2.   

Abstract

Intravitreal injection is one of the major administration routes for the treatment of posterior ocular diseases. Intravitreal therapeutics usually suffer from unsatisfactory efficacy owing to fast clearance from the vitreous humour and insufficient distribution into the retina. Engineered nanoparticles have been applied for specific tissue targeting over the past decades. In this review, we summarize the most recent research utilizing intravitreal nanoparticles to deliver therapeutics to the retina. Herein, the achievement made in preclinical research and challenges remaining in the field are highlighted. Parameters including size, charge, stability and choice of modified ligand on intraocular distribution and transport are also systematically discussed based on a proposed pharmacokinetic model. We provide insights for rational design principles for intravitreal nanoparticles for targeted retinal delivery.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31102730     DOI: 10.1016/j.drudis.2019.05.005

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  7 in total

1.  Low-dose melittin is safe for intravitreal administration and ameliorates inflammation in an experimental model of uveitis.

Authors:  Brenda Fernanda Moreira Castro; Carolina Nunes da Silva; Lídia Pereira Barbosa Cordeiro; Sarah Pereira de Freitas Cenachi; Daniel Vitor Vasconcelos-Santos; Renes Resende Machado; Luiz Guilherme Dias Heneine; Luciana Maria Silva; Armando Silva-Cunha; Silvia Ligório Fialho
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-05-11

2.  An intravitreal implant injection method for sustained drug delivery into mouse eyes.

Authors:  Young Joo Sun; Cheng-Hui Lin; Man-Ru Wu; Soo Hyeon Lee; Jing Yang; Caitlin R Kunchur; Elena M Mujica; Bryce Chiang; Youn Soo Jung; Sui Wang; Vinit B Mahajan
Journal:  Cell Rep Methods       Date:  2021-12-06

Review 3.  Considerations for Polymers Used in Ocular Drug Delivery.

Authors:  Megan M Allyn; Richard H Luo; Elle B Hellwarth; Katelyn E Swindle-Reilly
Journal:  Front Med (Lausanne)       Date:  2022-01-28

4.  A Review of Gene, Drug and Cell-Based Therapies for Usher Syndrome.

Authors:  Lucy S French; Carla B Mellough; Fred K Chen; Livia S Carvalho
Journal:  Front Cell Neurosci       Date:  2020-07-09       Impact factor: 5.505

5.  Association of the Somatostatin Analog Octreotide With Magnetic Nanoparticles for Intraocular Delivery: A Possible Approach for the Treatment of Diabetic Retinopathy.

Authors:  Rosario Amato; Martina Giannaccini; Massimo Dal Monte; Maurizio Cammalleri; Alessandro Pini; Vittoria Raffa; Matteo Lulli; Giovanni Casini
Journal:  Front Bioeng Biotechnol       Date:  2020-02-25

6.  The effects of PEGylation on LNP based mRNA delivery to the eye.

Authors:  Renee C Ryals; Siddharth Patel; Chris Acosta; Madison McKinney; Mark E Pennesi; Gaurav Sahay
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

7.  A Long-Acting Curcumin Nanoparticle/In Situ Hydrogel Composite for the Treatment of Uveal Melanoma.

Authors:  Lingxiao Xie; Weizhou Yue; Khaled Ibrahim; Jie Shen
Journal:  Pharmaceutics       Date:  2021-08-25       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.